# Odimma Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/odimma-therapeutics

- Industry: Biotechnology
- Headquarters: Strasbourg, France
- Website: www.odimma-therapeutics.com
- Total disclosed funding: $2.1M
- Latest round: Seed (Sep 19, 2022)
- Investors on record: 1

## About

Based in Strasbourg, France, and founded in 2017 by Jean-Marc Limacher, and Jessica Matta (CEO), Odimma Therapeutics operates as a biotechnology company specializing in personalized cancer immunotherapy and customized medicine. In April 2023, Odimma Therapeutics raised EUR 2 million in seed funding from Alsace Business Angels, Angels Santé, Bpifrance, Capital Grand Est, etc. 

Odimma Therapeutics has developed an immunotherapy drug that aims to enhance personalized cancer immunotherapy. By utilizing a platform that combines three immune players, this drug can work in synergy with the immune system to induce and amplify an immune response. The firm empowers patients to effectively treat tumors with fewer side effects. In addition, the company's mission is to advance immunotherapy treatments and improve the lives of cancer patients.

The company plans to use the April 2023 funding to further the development of its ODI-2001, personalized immunotherapy against cancer.

## Funding rounds

- Seed, Sep 19, 2022, $0.9M — Capital Grand Est
- Seed, Oct 20, 2021, $0.6M — Capital Grand Est
- Seed, Jun 15, 2020, $0.6M — Capital Grand Est

## Investors

- Capital Grand Est (https://capitalatlas.ai/funds/capital-grand-est) — Seed